CVS Corporation 10-Q Summary: Period Ended September 30, 2006
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2006, and the thirty-nine weeks ended on that date. CVS Corporation operates as the largest retail pharmacy in the United States, managing two primary segments: Retail Pharmacy (6,157 stores as of period end) and Pharmacy Benefit Management (PBM). The reporting period includes the financial impact of the June 2, 2006, acquisition of approximately 700 standalone drugstores and a distribution center from Albertson's, Inc. for $4.0 billion.
Key Financial Metrics
| Metric (in millions) | 13 Weeks Ended Sep 30, 2006 | 39 Weeks Ended Sep 30, 2006 |
|---|---|---|
| Net Revenues | $11,206.9 | $31,747.5 |
| Gross Profit | $3,080.3 | $8,573.7 |
| Operating Profit | $536.8 | $1,692.3 |
| Net Earnings | $284.2 | $951.7 |
| Diluted EPS | $0.33 | $1.11 |
| Cash from Operations (39 weeks) | $993.2 | |
| Total Debt (Short-term + Long-term) | $6,486.5 | |
| Cash and Equivalents | $394.6 |
Margins: Gross profit margin was 27.5% for the quarter and 27.0% for the year-to-date period. Operating margin was 4.8% for the quarter and 5.3% for the year-to-date.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 24.9% for the quarter and 16.4% year-to-date compared to 2005. This growth was driven by the Albertsons acquisition (contributing ~1,300 basis points in Q3), new store openings, and same-store sales increases of 9.1% (Q3) and 8.0% (YTD).
- Profitability: Net earnings rose 12.5% in the quarter and 16.3% year-to-date. Operating profit increased due to revenue growth, partially offset by higher operating expenses.
- Expense Increases: Total operating expenses rose to 22.7% of revenue (Q3) from 21.9% in the prior year. This increase is attributed to the adoption of SFAS No. 123(R) regarding share-based payments and integration costs for the Albertsons acquisition.
- Interest Expense: Net interest expense surged to $75.2 million (Q3) from $27.3 million in 2005, reflecting higher debt balances and interest rates associated with financing the Albertsons deal.
- Balance Sheet: Total assets grew from $15.3 billion to $21.1 billion, primarily due to the acquisition. Short-term debt increased significantly to $3.16 billion to fund the transaction, while long-term debt rose to $3.28 billion following the issuance of $1.5 billion in senior notes.
Guidance, Outlook, and Risks
Recent Developments: On November 1, 2006, CVS entered into a definitive merger agreement with Caremark Rx, Inc., structured as a merger of equals. Closing is expected within six to twelve months, subject to regulatory and shareholder approval.
Liquidity and Capital: Management anticipates cash flows from operations, commercial paper, and long-term borrowings will fund growth. The company plans to retire the $1.0 billion bridge loan facility in Q4 2006 using proceeds from a sale-leaseback transaction of acquired real estate.
Risks and Contingencies:
- Regulatory and Reimbursement: Risks include efforts by third-party payers to reduce prescription costs, the impact of Medicare Part D on gross profit rates, and potential reductions in Medicaid reimbursement rates under the Deficit Reduction Act of 2005.
- Integration: Success depends on integrating the Albertsons Standalone Drug Business and the future Caremark merger.
- Legal Proceedings: CVS is cooperating in an investigation by Rhode Island authorities regarding business relationships between former state legislators and various companies, including CVS. The outcome is uncertain.
- Accounting Changes: The company is evaluating the impact of new standards SFAS No. 158 (pension accounting) and SFAS No. 157 (fair value measurement).
Investor Verification Checklist
- Verify the final purchase price allocation for the Albertsons acquisition, as the current allocation is preliminary and subject to material change.
- Monitor the status of the Caremark merger, including regulatory approvals and potential antitrust challenges.
- Assess the impact of the Deficit Reduction Act of 2005 on Medicaid reimbursement rates, scheduled to take effect in Q1 2007.
- Review the company's ability to execute the planned sale-leaseback transaction to retire the bridge loan facility.
- Track the resolution of the Rhode Island legal investigation and any potential financial liabilities.
- Confirm the effectiveness of cost-saving measures to offset the increased operating expenses from SFAS 123(R) adoption and integration costs.